Local Allergic Rhinitis Often Progresses Over Time

This article originally appeared here.
Share this content:
Local Allergic Rhinitis Often Progresses Over Time
Local Allergic Rhinitis Often Progresses Over Time

THURSDAY, Aug. 31, 2017 (HealthDay News) -- Patients with local allergic rhinitis (LAR) show worsening of rhinitis, greater tendency toward development of asthma, and impairment of quality of life after 10 years, but have a similar rate of development of allergic rhinitis with systemic atopy as controls, according to research published online Aug. 22 in Allergy.

Carmen Rondon, M.D., Ph.D., from the IBIMA-Regional University Hospital of Málaga in Spain, and colleagues examined the natural history of a population with LAR in a 10-year follow-up study of a cohort of 176 patients with LAR of recent onset and 115 age- and sex-matched controls.

The researchers found that LAR patients experienced a significant and clinically relevant worsening of the rhinitis after 10 years, with increase of emergency assistance, development of asthma, loss of allergen tolerance, and impairment of quality of life. After five years, the worsening became significant, and progressed throughout 10 years. Patients and controls had a similar rate of development of allergic rhinitis with systemic atopy (9.7 versus 7.8 percent; P = 0.623). Conversion to systemic atopic occurred after 10 years in five patients (3 percent).

"LAR is a well-differentiated clinical entity with a low rate of development of systemic atopy, a natural evolution towards worsening, and a risk factor for suffering asthma," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »